CoChat

Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia.

Griffin, A. T., Peyrani, P., Wiemken, T. L., Ramirez, J. A., Arnold, F. W. · 2013 · Infection

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Purpose The Infectious Diseases Society of America has recommended empiric therapy active against methicillin-resistant Staphylococcus aureus (MRSA) for all community-acquired pneumonia (CAP) patients admitted to the intensive care unit (ICU). However, there is sparse data to support this recommendation. The objective of our study was to ascertain if such a practice improves outcomes.Methods This study was a secondary, retrospective analysis of the Community-Acquired Pneumonia Organization (CAPO) international database on CAP. Outcomes in patients admitted to the ICU were compared according to empiric initiation of anti-MRSA therapy (vancomycin or linezolid) with standard ICU CAP therapy (MRSA therapy group) or standard therapy alone for ICU CAP (standard therapy group).Results A total of 621 patients were identified with ICU pneumonia, of whom 57 patients had been initiated empirically on vancomycin or linezolid (MRSA therapy group). Patients of the MRSA therapy group had more comorbidities and were more severely ill than those of the standard therapy group. However, there were no statistical differences between the MRSA therapy group and standard therapy group for the primary outcomes of in-hospital and 28-day mortality, length of stay and time to clinical stability.Conclusions These findings suggest that empiric MRSA therapy in all ICU CAP patients may not improve outcomes and argue for clinician review of local epidemiologic trends on MRSA prevalence to ascertain the need for empiric MRSA coverage.

Overview

Integrity signals

Registry

Crossref · 10.1007/s15010-012-0363-1

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 18

Metadata

Authors
Griffin, A. T., Peyrani, P., Wiemken, T. L., Ramirez, J. A., & Arnold, F. W.
Affiliations
University of Louisville (US)
Corresponding author
Griffin, A. T.
Venue
Infection
Published
2012-11-07
Volume
41
Issue
2
Pages
517-523
ISSN
  • 0300-8126 (ISSN-L)
  • 1439-0973
OpenAlex
W2094857325
Cited by
17
References
23
Citations by year
2026: 1 · 2025: 1 · 2021: 4 · 2020: 2 · 2019: 1 · 2017: 2 · 2016: 1 · 2015: 3 · 2013: 2
FWCI
1.19
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Infection (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
Keywords
community-acquired pneumonia, methicillin-resistant Staphylococcus aureus, empirical antibiotic therapy, intensive care unit admission, vancomycin, linezolid, in-hospital mortality, 28-day mortality, length of hospital stay, clinical stability, MRSA prevalence
MeSH terms
Linezolid, Acetamides, Adult, Aged, Anti-Bacterial Agents, Female, Humans, Intensive Care Units, Length of Stay, Male, Middle Aged, Retrospective Studies, Staphylococcal Infections, Vancomycin, Comorbidity, Prevalence, Proportional Hazards Models, Treatment Outcome, Hospital Mortality, Community-Acquired Infections, Pneumonia, Bacterial, Oxazolidinones, Empirical Research, Methicillin-Resistant Staphylococcus aureus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. https://app.cochat.ai/papers/10.1007/s15010-012-0363-1
The paper
Griffin, A. T., Peyrani, P., Wiemken, T. L., Ramirez, J. A., & Arnold, F. W. (2013). Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. Infection. https://doi.org/10.1007/s15010-012-0363-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.